Ordered and deterministic cancer genome evolution after p53 loss

Timour Baslan(Memorial Sloan Kettering Cancer Center), John P. Morris(University of North Carolina at Chapel Hill), Zhen Zhao(Memorial Sloan Kettering Cancer Center), José Reyes(Memorial Sloan Kettering Cancer Center), Yu-Jui Ho(Memorial Sloan Kettering Cancer Center), Kaloyan M. Tsanov(Memorial Sloan Kettering Cancer Center), Jonathan Bermeo(Memorial Sloan Kettering Cancer Center), Sha Tian(Memorial Sloan Kettering Cancer Center), Sean X. Zhang(Memorial Sloan Kettering Cancer Center), Gokce Askan(Memorial Sloan Kettering Cancer Center), Aslihan Yavas(Memorial Sloan Kettering Cancer Center), Nicolas Lecomte(Memorial Sloan Kettering Cancer Center), Amanda Erakky(Memorial Sloan Kettering Cancer Center), Anna M. Varghese(Memorial Sloan Kettering Cancer Center), Amy Zhang(Ontario Institute for Cancer Research), Jude Kendall(Cold Spring Harbor Laboratory), Elena Ghiban(Cold Spring Harbor Laboratory), Lubomir Chorbadjiev(Technical University of Sofia), Jie Wu(IPS Research (United States)), Nevenka Dimitrova(IPS Research (United States)), Kalyani Chadalavada(Memorial Sloan Kettering Cancer Center), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Chaitanya Bandlamudi(Memorial Sloan Kettering Cancer Center), Yixiao Gong(Memorial Sloan Kettering Cancer Center), Mark T.A. Donoghue(Memorial Sloan Kettering Cancer Center), Nicholas D. Socci(Memorial Sloan Kettering Cancer Center), A. Krasnitz(Cold Spring Harbor Laboratory), Faiyaz Notta(Ontario Institute for Cancer Research), Steve D. Leach(Dartmouth College), Christine A. Iacobuzio–Donahue(Memorial Sloan Kettering Cancer Center), Scott W. Lowe(Memorial Sloan Kettering Cancer Center)
Nature
August 17, 2022
Cited by 233Open Access
Full Text

Abstract

, the patterns through which heterogenous TP53 (encoding human p53) mutant genomes emerge and influence tumorigenesis remain poorly understood. Here, in a mouse model of pancreatic ductal adenocarcinoma that reports sporadic p53 loss of heterozygosity before cancer onset, we find that malignant properties enabled by p53 inactivation are acquired through a predictable pattern of genome evolution. Single-cell sequencing and in situ genotyping of cells from the point of p53 inactivation through progression to frank cancer reveal that this deterministic behaviour involves four sequential phases-Trp53 (encoding mouse p53) loss of heterozygosity, accumulation of deletions, genome doubling, and the emergence of gains and amplifications-each associated with specific histological stages across the premalignant and malignant spectrum. Despite rampant heterogeneity, the deletion events that follow p53 inactivation target functionally relevant pathways that can shape genomic evolution and remain fixed as homogenous events in diverse malignant populations. Thus, loss of p53-the 'guardian of the genome'-is not merely a gateway to genetic chaos but, rather, can enable deterministic patterns of genome evolution that may point to new strategies for the treatment of TP53-mutant tumours.


Related Papers

No related papers found

Powered by citation graph analysis